Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Medgenics — Q3 2015 Earnings Presentation

15 slides from Aevi Genomic Medicine's earnings presentation, Oct 22, 2015

  1. Slide 1: Q3 2015 Results

    Q3 2015 Results October 22, 2015

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results

  3. Slide 3: Agenda

    Agenda 3 • Q3 Operational Update • Q3 Financial Update • 2015 Milestones

  4. Slide 4: Business Model Evolution: Gene Therapy to Genomic Medicine

    Business Model Evolution: Gene Therapy to Genomic Medicine 4 Diverse Limited Medgenics capabilities Ex vivo Gene Therapy • TARGT EPO • TARGT GLP - 2 Time Genomic Medicine • C ommercial capabilities • Further pipeline diversification Genomic Drug Development • World - class biobank and analytics • G

  5. Slide 5: Q3 Operational Update

    Q3 Operational Update 5 • Acquired neuroFix , providing access to a Phase 2 - ready program, NFC - 1 – First program to be announced from ongoing collaboration with Center for Applied Genomics (CAG ) at The Children’s Hospital of Philadelphia (CHOP) – Breakthrough discovery: mGluR mutations cause ~2

  6. Slide 6: NFC-1 Summary

    NFC - 1 Summary • First program from the collaboration – Phase 2 ready program via neuroFix acquisition • P rogram in mGluR + ADHD is highly de - risked – Extensive safety database – Compelling Phase 1b efficacy signal in mGluR+ ADHD • Potential rapid path to approval in 22q11.2 DS – Potentially lar

  7. Slide 7: NFC-1 GREAT Study Summary

    NFC - 1 GREAT Study Summary • Strong efficacy signal detected in several validated ADHD scales • Improvement in multiple symptoms noted by caregivers – I nattention, hyperactivity, anxiety, mood disorders • Treatment effect more robust over time & higher doses • Genetic biomarker predictive of respo

  8. Slide 8: Next Steps: mGluR+ ADHD

    Next Steps: mGluR+ ADHD Phase 2/3 trial in Tier 1/2 mGluR + ADHD • Objective: Identify optimal dose and confirm enhanced response in mGluR network mutation positive patients – Primary endpoints: ADHD RS, CGI - I – Powered to serve as pivotal trial – Top - line data anticipated H216 • Additional stud

  9. Slide 9: Next Steps: 22q11.2 Deletion Syndrome

    Next Steps: 22q11.2 Deletion Syndrome • Phase 1/2 indication & dose finding study – File IND 4Q15 – Explore major neuropsychiatric disorders: ADHD, Anxiety, Mood – Initial data expected mid - 2016 – Transition to pivotal trial in one or more disorders – Rapid path to approval based on potential of O

  10. Slide 10: Financial Update

    Financial Update ‘0 medgenics

  11. Slide 11: Q3 2015 Financial Update (3 months)

    Q3 2015 Financial Update (3 months) • For the quarter ended Sept. 30, 2015, the company reported a net loss of $16.5MM increasing from $3.0MM for the same period in 2014 due mainly to a non - recurring R&D charges related to the acquisition of NFC - 1 of $8.2MM. Included in the net loss of $16.5MM i

  12. Slide 12: Q3 2015 Financial Update (9 months)

    Q3 2015 Financial Update (9 months) • For the first nine months of 2015, the company reported a net loss of $31.5MM increasing from $12.2MM for the same period in 2014 due mainly to a non - recurring R&D charges related to the acquisition of NFC - 1 of $8.2MM. Included in the net loss of $31.5MM is

  13. Slide 13: Q3 2015 Financial Update (Cash Balance)

    Q3 2015 Financial Update (Cash Balance) • Company’s cash balance as of Sept. 30, 2015 was $17.7MM • Subsequent to the end of the quarter the company completed a registered public offering of 7,078,250 shares at $6.50/share • Net proceeds from the transaction were $42.9MM • Current cash balance of >$

  14. Slide 14: NFC-1 Near-term Milestones

    NFC - 1 Near - term Milestones 14 PROGRAM TIMING mGluR + ADHD GREAT Study Data presented at AACAP Oct 31 Request type “C” meeting with the FDA Q4 15 Initiate Phase 2/3 dose finding pivotal trial Q1 16 Initial data readout H2 16 22q11.2 Deletion Syndrome Submit IND for 22q11.2 DS Q4 15 Initiate explo

  15. Slide 15: Summary

    Summary • Transformative quarter for the Company – Acquisition of NFC - 1 program – Successful equity offering • Accelerates the Company’s transition to genomic m edicine approach to drug development • NFC - 1 acquisition is the first of multiple potential deals from Medgenics/CHOP collaboration 15

Medgenics — Q3 2015 Earnings Presentation on 6ix